schliessen

Filtern

 

Bibliotheken

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality—especially cardiovascular mortality—in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan mi... Full description

Journal Title: The Lancet (British edition) 2003-08-23, Vol.362 (9384), p.619-620
Main Author: Lindholm, Lars H
Other Authors: Dahlöf, Björn , Edelman, Jonathan M , Ibsen, Hans , Borch-Johnsen, Knut , Olsen, Michael Hecht , Snapinn, Steven , Wachtell, Kristian
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/12944063
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_73594478
title: Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
format: Article
creator:
  • Lindholm, Lars H
  • Dahlöf, Björn
  • Edelman, Jonathan M
  • Ibsen, Hans
  • Borch-Johnsen, Knut
  • Olsen, Michael Hecht
  • Snapinn, Steven
  • Wachtell, Kristian
subjects:
  • Abridged Index Medicus
  • Aged
  • Analysis
  • Antihypertensive Agents - therapeutic use
  • Arrhythmias, Cardiac - epidemiology
  • Arrhythmias, Cardiac - mortality
  • Atenolol
  • Atenolol - therapeutic use
  • Atrial fibrillation
  • Atrial Fibrillation - epidemiology
  • Atrial Fibrillation - mortality
  • Cardiac arrest
  • Cardiac patients
  • Cardiovascular disease
  • Cardiovascular diseases
  • Clinical trials
  • Comorbidity
  • Death
  • Death, Sudden, Cardiac - epidemiology
  • Death, Sudden, Cardiac - prevention & control
  • Defibrillators
  • Diabetes
  • Diabetes Complications
  • Diabetes mellitus
  • Diabetes Mellitus - epidemiology
  • Diabetes Mellitus - mortality
  • Diabetics
  • Drug therapy
  • Electrocardiography
  • Female
  • Fibrillation
  • Health aspects
  • Heart
  • Humans
  • Hypertension
  • Hypertension - drug therapy
  • Hypertension - epidemiology
  • Hypertension - mortality
  • Hypertrophy
  • Hypertrophy, Left Ventricular - epidemiology
  • Hypertrophy, Left Ventricular - mortality
  • Losartan
  • Losartan - therapeutic use
  • Male
  • Mortality
  • Patients
  • Prevention
  • Reduction
  • Ventricle
ispartof: The Lancet (British edition), 2003-08-23, Vol.362 (9384), p.619-620
description: In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality—especially cardiovascular mortality—in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis. 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0·027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.2955647
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_73594478
sourceformatXML
sourcesystemPC
galeidA107180298
sourcerecordidA107180298
originalsourceidFETCH-LOGICAL-1700t-5c7c4dd7f2f55af27b2d7beabf969db6c66e3178c4bb174a8f4a15c6708ea1173
addsrcrecordideNqNk-9r1DAch4so7pz-CUpQEAVvJm1-NPpCxrjp4MAXKvhCCGnyzV1GrzmTVNl_b2473G3oNgopaZ_Pk4Z8WlVPCT4gmPC3XzCheMpFw1_h5jWhpG2m8l41IVTQKaPi-_1q8hfZqx6ldIoxphyzh9UeqSWlmDeT6sfMOTAZBYf6kHTMekBhQGm0FgZkdLReG2RB5yXyA1pDWPeAfvsyLW86yJDeIauzRi6GFcpLQPOT4xlKebRnj6sHTvcJnmzv-9W349nXo0_T-eePJ0eH8ykRGOcpM8JQa4WrHWPa1aKrrehAd05yaTtuOIeGiNbQriOC6tZRTZjhAregCRHNfvXywruO4ecIKauVTwb6Xg8QxqREw8p-RVvAF9fA0zDGoXybqjGXsmGk3uie_48iUhLcMtpcqha6B-UHF3LUZrOuOmSUC0kb0t5IEVk8nEl2M4UFaXEtN66Df1DlsrDyJgzgfHl-RXu3wM4Kb3YC3Zj8AKkMyS-WOS30mNJV_13wHTu7wE0MKUVwah39SsczRbDadFqdd1ptCqtwo847rWTJPdsex9itwF6mtiUuwPtrYuOzzj4MZb--v1X_4SINpaG_PESVjIfBgPWx_BnKBn-L4Q-ylRHO
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid199108543
display
typearticle
titleEffect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
sourceAlma/SFX Local Collection
creatorLindholm, Lars H ; Dahlöf, Björn ; Edelman, Jonathan M ; Ibsen, Hans ; Borch-Johnsen, Knut ; Olsen, Michael Hecht ; Snapinn, Steven ; Wachtell, Kristian
creatorcontribLindholm, Lars H ; Dahlöf, Björn ; Edelman, Jonathan M ; Ibsen, Hans ; Borch-Johnsen, Knut ; Olsen, Michael Hecht ; Snapinn, Steven ; Wachtell, Kristian ; for the LIFE study group ; LIFE study group
descriptionIn the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality—especially cardiovascular mortality—in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis. 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0·027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(03)14183-9
3PMID: 12944063
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subjectAbridged Index Medicus ; Aged ; Analysis ; Antihypertensive Agents - therapeutic use ; Arrhythmias, Cardiac - epidemiology ; Arrhythmias, Cardiac - mortality ; Atenolol ; Atenolol - therapeutic use ; Atrial fibrillation ; Atrial Fibrillation - epidemiology ; Atrial Fibrillation - mortality ; Cardiac arrest ; Cardiac patients ; Cardiovascular disease ; Cardiovascular diseases ; Clinical trials ; Comorbidity ; Death ; Death, Sudden, Cardiac - epidemiology ; Death, Sudden, Cardiac - prevention & control ; Defibrillators ; Diabetes ; Diabetes Complications ; Diabetes mellitus ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - mortality ; Diabetics ; Drug therapy ; Electrocardiography ; Female ; Fibrillation ; Health aspects ; Heart ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypertension - epidemiology ; Hypertension - mortality ; Hypertrophy ; Hypertrophy, Left Ventricular - epidemiology ; Hypertrophy, Left Ventricular - mortality ; Losartan ; Losartan - therapeutic use ; Male ; Mortality ; Patients ; Prevention ; Reduction ; Ventricle
ispartofThe Lancet (British edition), 2003-08-23, Vol.362 (9384), p.619-620
rights
02003 Elsevier Ltd
1COPYRIGHT 2003 Elsevier B.V.
2Copyright Lancet Ltd. Aug 23, 2003
3Copyright Elsevier Limited Aug 23, 2003
lds50peer_reviewed
citedbyFETCH-LOGICAL-1700t-5c7c4dd7f2f55af27b2d7beabf969db6c66e3178c4bb174a8f4a15c6708ea1173
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12944063$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Lindholm, Lars H
1Dahlöf, Björn
2Edelman, Jonathan M
3Ibsen, Hans
4Borch-Johnsen, Knut
5Olsen, Michael Hecht
6Snapinn, Steven
7Wachtell, Kristian
8for the LIFE study group
9LIFE study group
title
0Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
1The Lancet (British edition)
addtitleLancet
descriptionIn the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality—especially cardiovascular mortality—in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis. 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0·027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation.
subject
0Abridged Index Medicus
1Aged
2Analysis
3Antihypertensive Agents - therapeutic use
4Arrhythmias, Cardiac - epidemiology
5Arrhythmias, Cardiac - mortality
6Atenolol
7Atenolol - therapeutic use
8Atrial fibrillation
9Atrial Fibrillation - epidemiology
10Atrial Fibrillation - mortality
11Cardiac arrest
12Cardiac patients
13Cardiovascular disease
14Cardiovascular diseases
15Clinical trials
16Comorbidity
17Death
18Death, Sudden, Cardiac - epidemiology
19Death, Sudden, Cardiac - prevention & control
20Defibrillators
21Diabetes
22Diabetes Complications
23Diabetes mellitus
24Diabetes Mellitus - epidemiology
25Diabetes Mellitus - mortality
26Diabetics
27Drug therapy
28Electrocardiography
29Female
30Fibrillation
31Health aspects
32Heart
33Humans
34Hypertension
35Hypertension - drug therapy
36Hypertension - epidemiology
37Hypertension - mortality
38Hypertrophy
39Hypertrophy, Left Ventricular - epidemiology
40Hypertrophy, Left Ventricular - mortality
41Losartan
42Losartan - therapeutic use
43Male
44Mortality
45Patients
46Prevention
47Reduction
48Ventricle
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2003
recordtypearticle
recordideNqNk-9r1DAch4so7pz-CUpQEAVvJm1-NPpCxrjp4MAXKvhCCGnyzV1GrzmTVNl_b2473G3oNgopaZ_Pk4Z8WlVPCT4gmPC3XzCheMpFw1_h5jWhpG2m8l41IVTQKaPi-_1q8hfZqx6ldIoxphyzh9UeqSWlmDeT6sfMOTAZBYf6kHTMekBhQGm0FgZkdLReG2RB5yXyA1pDWPeAfvsyLW86yJDeIauzRi6GFcpLQPOT4xlKebRnj6sHTvcJnmzv-9W349nXo0_T-eePJ0eH8ykRGOcpM8JQa4WrHWPa1aKrrehAd05yaTtuOIeGiNbQriOC6tZRTZjhAregCRHNfvXywruO4ecIKauVTwb6Xg8QxqREw8p-RVvAF9fA0zDGoXybqjGXsmGk3uie_48iUhLcMtpcqha6B-UHF3LUZrOuOmSUC0kb0t5IEVk8nEl2M4UFaXEtN66Df1DlsrDyJgzgfHl-RXu3wM4Kb3YC3Zj8AKkMyS-WOS30mNJV_13wHTu7wE0MKUVwah39SsczRbDadFqdd1ptCqtwo847rWTJPdsex9itwF6mtiUuwPtrYuOzzj4MZb--v1X_4SINpaG_PESVjIfBgPWx_BnKBn-L4Q-ylRHO
startdate20030823
enddate20030823
creator
0Lindholm, Lars H
1Dahlöf, Björn
2Edelman, Jonathan M
3Ibsen, Hans
4Borch-Johnsen, Knut
5Olsen, Michael Hecht
6Snapinn, Steven
7Wachtell, Kristian
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
90TT
100TZ
110U~
123V.
137QL
147QP
157RV
167TK
177U7
187U9
197X7
207XB
2188A
2288C
2388E
2488G
2588I
268AF
278AO
288C1
298C2
308FE
318FH
328FI
338FJ
348FK
358G5
36ABUWG
37AN0
38ASE
39AZQEC
40BBNVY
41BEC
42BENPR
43BHPHI
44C1K
45DWQXO
46FPQ
47FYUFA
48GHDGH
49GNUQQ
50GUQSH
51H94
52HCIFZ
53K6X
54K9-
55K9.
56KB0
57KB~
58LK8
59M0R
60M0S
61M0T
62M1P
63M2M
64M2O
65M2P
66M7N
67M7P
68MBDVC
69NAPCQ
70PQEST
71PQQKQ
72PQUKI
73Q9U
74S0X
757X8
sort
creationdate20030823
titleEffect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
authorLindholm, Lars H ; Dahlöf, Björn ; Edelman, Jonathan M ; Ibsen, Hans ; Borch-Johnsen, Knut ; Olsen, Michael Hecht ; Snapinn, Steven ; Wachtell, Kristian
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1700t-5c7c4dd7f2f55af27b2d7beabf969db6c66e3178c4bb174a8f4a15c6708ea1173
rsrctypearticles
prefilterarticles
languageeng
creationdate2003
topic
0Abridged Index Medicus
1Aged
2Analysis
3Antihypertensive Agents - therapeutic use
4Arrhythmias, Cardiac - epidemiology
5Arrhythmias, Cardiac - mortality
6Atenolol
7Atenolol - therapeutic use
8Atrial fibrillation
9Atrial Fibrillation - epidemiology
10Atrial Fibrillation - mortality
11Cardiac arrest
12Cardiac patients
13Cardiovascular disease
14Cardiovascular diseases
15Clinical trials
16Comorbidity
17Death
18Death, Sudden, Cardiac - epidemiology
19Death, Sudden, Cardiac - prevention & control
20Defibrillators
21Diabetes
22Diabetes Complications
23Diabetes mellitus
24Diabetes Mellitus - epidemiology
25Diabetes Mellitus - mortality
26Diabetics
27Drug therapy
28Electrocardiography
29Female
30Fibrillation
31Health aspects
32Heart
33Humans
34Hypertension
35Hypertension - drug therapy
36Hypertension - epidemiology
37Hypertension - mortality
38Hypertrophy
39Hypertrophy, Left Ventricular - epidemiology
40Hypertrophy, Left Ventricular - mortality
41Losartan
42Losartan - therapeutic use
43Male
44Mortality
45Patients
46Prevention
47Reduction
48Ventricle
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Lindholm, Lars H
1Dahlöf, Björn
2Edelman, Jonathan M
3Ibsen, Hans
4Borch-Johnsen, Knut
5Olsen, Michael Hecht
6Snapinn, Steven
7Wachtell, Kristian
8for the LIFE study group
9LIFE study group
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8News PRO
9Pharma and Biotech Premium PRO
10Global News & ABI/Inform Professional
11ProQuest Central (Corporate)
12Bacteriology Abstracts (Microbiology B)
13Calcium & Calcified Tissue Abstracts
14Nursing & Allied Health Database
15Neurosciences Abstracts
16Toxicology Abstracts
17Virology and AIDS Abstracts
18Health & Medical Collection
19ProQuest Central (purchase pre-March 2016)
20Biology Database (Alumni Edition)
21Healthcare Administration Database (Alumni)
22Medical Database (Alumni Edition)
23Psychology Database (Alumni)
24Science Database (Alumni Edition)
25STEM Database
26ProQuest Pharma Collection
27Public Health Database
28Lancet Titles
29ProQuest SciTech Collection
30ProQuest Natural Science Collection
31Hospital Premium Collection
32Hospital Premium Collection (Alumni Edition)
33ProQuest Central (Alumni) (purchase pre-March 2016)
34Research Library (Alumni Edition)
35ProQuest Central (Alumni Edition)
36British Nursing Database
37British Nursing Index
38ProQuest Central Essentials
39Biological Science Collection
40eLibrary
41ProQuest Central
42Natural Science Collection
43Environmental Sciences and Pollution Management
44ProQuest Central Korea
45British Nursing Index (BNI) (1985 to Present)
46Health Research Premium Collection
47Health Research Premium Collection (Alumni)
48ProQuest Central Student
49Research Library Prep
50AIDS and Cancer Research Abstracts
51SciTech Premium Collection
52British Nursing Index
53Consumer Health Database (Alumni Edition)
54ProQuest Health & Medical Complete (Alumni)
55Nursing & Allied Health Database (Alumni Edition)
56ProQuest Newsstand Professional
57ProQuest Biological Science Collection
58Consumer Health Database
59Health & Medical Collection (Alumni Edition)
60Healthcare Administration Database
61Medical Database
62Psychology Database
63Research Library
64Science Database
65Algology Mycology and Protozoology Abstracts (Microbiology C)
66Biological Science Database
67Research Library (Corporate)
68Nursing & Allied Health Premium
69ProQuest One Academic Eastern Edition
70ProQuest One Academic
71ProQuest One Academic UKI Edition
72ProQuest Central Basic
73SIRS Editorial
74MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Lindholm, Lars H
1Dahlöf, Björn
2Edelman, Jonathan M
3Ibsen, Hans
4Borch-Johnsen, Knut
5Olsen, Michael Hecht
6Snapinn, Steven
7Wachtell, Kristian
aucorp
0for the LIFE study group
1LIFE study group
formatjournal
genrearticle
ristypeJOUR
atitleEffect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study
jtitleThe Lancet (British edition)
addtitleLancet
date2003-08-23
risdate2003
volume362
issue9384
spage619
epage620
pages619-620
issn0140-6736
eissn1474-547X
codenLANCAO
abstractIn the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality—especially cardiovascular mortality—in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis. 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0·027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation.
copEngland
pubElsevier Ltd
pmid12944063
doi10.1016/S0140-6736(03)14183-9